Abstract
The description of hyper-functional factor IX (FIX) Padua triggered the development of BAX 335, an AAV8-based hemophilia B gene therapy vector designed to compensate for low FIX protein expression levels by expressing the FIX Padua variant, thereby reducing the exposure to viral vector. The presence of inactive FIX protein at baseline hindered conventional FIX:Ag ELISA from contributing to a more profound understanding of clinical data from the BAX 335 Phase 1/2 study (ClinicalTrials.gov: NCT01687608). By applying phage display technology, a Fab2 mini-antibody selectively binding to FIX Padua was developed and used to establish a FIX Padua-specific ELISA. The assay adequately performed, utilizing human and monkey plasma samples, and enabled the selective quantification of FIX Padua protein in human plasma samples from the BAX 335 trial. The mini-antibody also allowed the development of a chromogenic FIX Padua-specific activity assay, which adequately performed in human and mouse plasma. Collectively, the isolated FIX Padua-specific mini-antibody enabled the development of transgene-product-specific assays, which should improve the monitoring of hemophilia B gene therapies. The approach applied here for FIX Padua could be levera...Continue Reading
References
May 20, 1988·Cell·B Furie, B C Furie
Oct 1, 1993·Science·M A KayK M Brinkhous
Feb 19, 1998·FEBS Letters·K E PerssonJ Stenflo
Jun 9, 2001·The New England Journal of Medicine·P M Mannucci, E G Tuddenham
Sep 1, 2005·Journal of Thrombosis and Haemostasis : JTH·K Hansson, J Stenflo
Oct 23, 2009·The New England Journal of Medicine·Paolo SimioniValder R Arruda
Jan 1, 2000·Methods in Molecular Medicine·B Jordan
Dec 14, 2011·The New England Journal of Medicine·Amit C NathwaniAndrew M Davidoff
Mar 31, 2012·Blood·Olivier Benveniste
Jun 29, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·E Tuddenham
Aug 25, 2012·Blood·Jonathan D FinnValder R Arruda
Oct 9, 2012·Blood·Alessio CantoreThierry Vandendriessche
Dec 7, 2013·The New England Journal of Medicine·Jerry S PowellUNKNOWN B-LONG Investigators
May 13, 2014·Immunotherapy·Leonard A Valentino
Sep 28, 2014·Blood·Peter W CollinsUNKNOWN paradigm 2 Investigators
Nov 25, 2014·Human Gene Therapy·Paul Edward MonahanR Jude Samulski
Jul 8, 2015·Journal of Thrombosis and Haemostasis : JTH·P E Monahan
Jul 8, 2015·Journal of Thrombosis and Haemostasis : JTH·J S Powell
Nov 29, 2015·Human Molecular Genetics·Katherine A High, Xavier M Anguela
Jan 13, 2016·Blood·Elena SantagostinoUNKNOWN PROLONG-9FP Investigators Study Group
Apr 9, 2016·Blood·Jason A Taylor, Rebecca Kruse-Jarres
Jul 14, 2016·Haemophilia : the Official Journal of the World Federation of Hemophilia·H T SpencerC B Doering
Oct 21, 2016·Journal of Pharmaceutical and Biomedical Analysis·Alfred WeberPeter L Turecek
Dec 7, 2017·The New England Journal of Medicine·Lindsey A GeorgeKatherine A High
Dec 16, 2017·Cell·David Lillicrap
Dec 17, 2017·Blood·Wolfgang MiesbachFrank W G Leebeek
Citations
Jul 10, 2019·Annual Review of Virology·Allison M Keeler, Terence R Flotte
Sep 25, 2019·Current Gene Therapy·Xiao-Lu GuoLung-Ji Chang
Oct 18, 2020·Blood·Barbara A KonklePaul E Monahan
Apr 14, 2020·Molecular Therapy. Methods & Clinical Development·Johannes LenglerHanspeter Rottensteiner